NWBO Stock Overview
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Northwest Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.48 |
| 52 Week High | US$1.09 |
| 52 Week Low | US$0.40 |
| Beta | -0.70 |
| 1 Month Change | -1.64% |
| 3 Month Change | -21.16% |
| 1 Year Change | -4.00% |
| 3 Year Change | -67.79% |
| 5 Year Change | 72.14% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| NWBO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.7% | -4.7% | -3.7% |
| 1Y | -4.0% | -2.7% | 20.2% |
Return vs Industry: NWBO underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: NWBO underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| NWBO volatility | |
|---|---|
| NWBO Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NWBO's share price has been volatile over the past 3 months.
Volatility Over Time: NWBO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 25 | Linda Powers | www.nwbio.com |
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer.
Northwest Biotherapeutics, Inc. Fundamentals Summary
| NWBO fundamental statistics | |
|---|---|
| Market cap | US$613.63m |
| Earnings (TTM) | -US$64.37m |
| Revenue (TTM) | US$1.93m |
298.9x
P/S Ratio-9.0x
P/E RatioIs NWBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NWBO income statement (TTM) | |
|---|---|
| Revenue | US$1.93m |
| Cost of Revenue | US$27.73m |
| Gross Profit | -US$25.80m |
| Other Expenses | US$38.58m |
| Earnings | -US$64.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.054 |
| Gross Margin | -1,335.30% |
| Net Profit Margin | -3,331.94% |
| Debt/Equity Ratio | -86.7% |
How did NWBO perform over the long term?
See historical performance and comparison